Vaccinex

About:

Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.

Website: http://www.vaccinex.com/

Twitter/X: vaccinex

Top Investors: Alzheimer's Drug Discovery Foundation, Albert Friedberg, Jacob Frieberg, Maurice Zauderer

Description:

Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.

Total Funding Amount:

$86.9M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Rochester, New York, United States

Founded Date:

1997-01-01

Contact Email:

info(AT)vaccinex.com

Founders:

Maurice Zauderer, Steven Cobourn

Number of Employees:

11-50

Last Funding Date:

2024-09-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai